Three of the best biotech stocks to buy now

Biotechnology firms are benefiting from demand from ageing populations. But as Dr Daniel Koller explains, there’s more to the biotech boom than that.

Each week, a professional investor tells MoneyWeek where he'd put his money now. This week:Dr Daniel Koller, lead manager of BB Biotech, Bellevue Asset Management.

Biotechnology firms are benefiting from rising demand for health-care products from ageing populations, and from increasingly health-conscious emerging markets. But there's more to the biotech boom than that.

The market's enthusiasm for new drugs has boosted biotechs' profits in recent years. This should continue through 2015, and will help firms to invest more in their new product pipelines, enabling them to move from being one-product wonders to becoming diversified, profitable, high-growth businesses.

In 2014, 41 new medicines were approved the second-highest figure since 1996. This should ensure strong momentum in 2015 and beyond. Investors can expect updates on pipeline products throughout the year.

As well as new products, big companies in the industry have many promising new projects and partnerships that they can use to boost sales. Investors should expect further merger and acquisition (M&A) activity in the sector.

In particular, growing pressure from 'biosimilars' essentially copies of existing biotechnology drugs means that pharmaceutical companies are displaying a healthy appetite for acquiring new products, which should keep M&A active this year.

Debates over drug pricing will continue. But targeted discounts and pricing studies should ensure that companies still make fair returns for the risks they take and the investment they have made.

Also, innovative drugs with higher cure rates and fewer side effects ultimately save money for health-care systems so such treatments should continue to enjoy strong pricing power. Antibiotics is one area that has already benefited from regulatory incentives.

It's not just big players such as Celgene and Gilead who could make billions of dollars when their respective cancer and hepatitis C drugs hit peak sales. A handful of mid-cap companies are also due to release key clinical data this year on products that could replace existing treatments.

So although biotech has been the best-performing sector since the financial crisis, we expect further growth in 2015 and beyond. That said, we believe the biggest innovators, with strong product pipelines, will be where the most interesting opportunities can be found.

Radius (Nasdaq: RDUS) is a mid-cap biotech that could introduce a new standard of care for a serious, costly disease severe post-menopausal osteoporosis. This leads to bone fractures that are often life changing and potentially fatal.

Radius's drug, abaloparatide, has been shown to be better than the current treatment. Radius owns 100% of the rights and plans to file for approval this year.

Isis Pharma (Nasdaq: ISIS) has a pipeline of more than 30 compounds based on "antisense" genetic technology. Many of these compounds address diseases with no treatments available. Isis makes good use of its pipeline partnering up with other companies to raise money to develop its drugs, for example.

Incyte's (Nasdaq: INCY) lead product, Jakafi, is on the market for patients with myelofibrosis (a rare bone-marrow cancer) and is well on its way to becoming a $1bn product in the US and Europe.

Following positive data from a Phase II trial on pancreatic cancer patients, we await trials on other solid tumours, which could further expand the market. Other compounds in development include an IDO inhibitor with potential to be part of the multi-billion market for novel immunotherapy agents for cancer.

Recommended

Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Share tips: eight stocks that should deliver robust returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular

The next 20 years: five new technologies on the horizon
Global Economy

The next 20 years: five new technologies on the horizon

What will everyday life be like in two decades’ time? Matthew Partridge peers into his crystal ball.
12 Nov 2020
This week’s rally in value stocks is just the beginning
Value investing

This week’s rally in value stocks is just the beginning

The arrival of a vaccine this week saw huge gains in the markets and investors switching out of big-tech growth stocks and into “value” stocks in more…
13 Nov 2020
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Nov 2020